Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMA402 first-in-human study in PRAME-positive recurrent or refractory solid tumors
NL-OMON59021Phase 2Recruiting
- Sponsor
- Immatics
- Start
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of IMA402, pembrolizumab and decitabine in Nonhematologic neoplasms (2 arms), sponsored by Immatics. Primary endpoints: Dose-limiting toxicities, Treatment-emergent adverse events and 3 more. Started Oct 2024; status: recruiting.
02
Drugs
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON59021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59021.